With thousands of opioid lawsuits waiting in the wings, several major drugmakers have been prepping their defenses for a precursor trial slated to begin next week in New York. Now, with the novel coronavirus continuing its spread, those companies face a delay on that trial—which, for them, might be a good thing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,